Adicet Bio (FRA:1IJA) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Adicet Bio's Capital Expenditure for the three months ended in Mar. 2024 was €-0.22 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-28.40 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Adicet Bio Capex-to-Operating-Income Historical Data

The historical data trend for Adicet Bio's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Capex-to-Operating-Income Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Adicet Bio's Capex-to-Operating-Income

For the Biotechnology subindustry, Adicet Bio's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adicet Bio's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Capex-to-Operating-Income falls into.

Adicet Bio Capex-to-Operating-Income Calculation

Adicet Bio's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-4.093)	/	-121.572
	=	N/A

Adicet Bio's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.22)	/	-28.401
	=	N/A

Adicet Bio (FRA:1IJA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Adicet Bio Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (FRA:1IJA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (FRA:1IJA) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

ACET:USA

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (FRA:1IJA) Headlines

No Headlines